免疫疗法联合靶向治疗对转移性结直肠癌的疗效及安全性研究

doi:10.3969/j.issn.1006-6233.2023.10.032

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1226 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate the efficacy and safety of carrellizumab combined with anti-angiogenic agents in the treatment of metastatic MSS colorectal cancer. Methods: A total of 40 colorectal patients with metastatic MSS were enrolled in the radiotherapy Department of Tangshan People's Hospital from June 2021 to June 2022, who received third-line treatment with carrilizumab combined with anti-angiogenic agents (fuquitinib/regorafenib) or single-agent anti-angiogenic agents (fuquitinib/regorafenib) (20 in the combination group and 20 in the monotherapy group). Overall survival (OS), disease control rate (DCR) and objective response rate (ORR) of the two groups were evaluated, and the incidence of adverse events in the two groups were statistically analyzed. Results: Compared with the monotherapy group, there was no significant difference in the general clinical data of the combined group. The median OS in the combination and monotherapy groups was 11 and 7.5 months, DCR was 85% and 60%, and ORR was 30% and 10%, respectively. The incidence of adverse events in the combination group and the monotherapy group was 95% and 90%, respectively. Most of the adverse events were grade 1-2, and the incidence of serious adverse events (≥ grade 3) was 15% and 10%, respectively, without grade 4 adverse events. The incidence of capillaries in combination group was higher than that in monotherapy group. Conclusion: The combination group has improved benefit for patients with OS, but the difference is not statistically significant compared with the monotherapy group. Immunotherapy combined with anti-angiogenic drugs is a promising strategy, and the combination of the two can improve the survival benefits of patients, showing better anti-tumor activity and high safety in the treatment of advanced metastatic colorectal cancer, providing an important basis for the development of immunotargeted therapy for CRC.

Key words： Metastatic colorectal cancer Carrilizumab Antiangiogenic drugs Clinical effect Adverse reaction

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Wei
	CAO Bo
	WANG Zhiwu
	et al

Cite this article:

WANG Wei,CAO Bo,WANG Zhiwu, et al. Efficacy and Safety of Immunotherapy Combined with Targeted Therapy for Metastatic Colorectal Cancer[J]. HeBei Med, 2023, 29(10): 1748-1753.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.10.032 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I10/1748

[1] Biller LH,Schrag D.Diagnosis and treatment of metastatic colorectal cancer:a review[J].JAMA,2021,325(7):669-685.
[2] Fan A,Wang B,Wang X,et al.Immunotherapy in colorectal cancer:current achievements and future perspective[J].Int Biol Sci,2021,17(14):3837-3849.
[3] 杨小荣,郑子雯,易韵.卡瑞利珠单抗对晚期卵巢癌患者术后血管内皮生长因子及肿瘤标志物水平的影响[J].临床合理用药杂志,2022,15(33):93-96.
[4] 马青青,杨玉丹,李小丽,等.卡瑞利珠单抗联合阿帕替尼对不同微卫星状态的晚期结直肠癌的疗效[J].河南医学研究,2022,31(7):1194-1198.
[5] 刘明锐,赵洪瑜.抗血管生成药物在结直肠癌治疗中的应用进展[J].癌症进展,2022,20(7):664-667,679.
[6] Yang Y.Cancer immunotherapy:harnessing the immune system to battle cancer[J].Clin Invest,2015,125(9):3335-3337.
[7] Song H,Liu X,Jiang L,et al.Current status and prospects of camrelizumab,a humanized antibody against programmed cell death receptor 1[J].Recent Pat Anticancer Drug Discov,2021,16(3):312-332.
[8] Liu J,Liu Q,Li Y,et al.Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer:an open-label phase II tria[J].Immunother Cancer,2020,8(1):696.
[9] Chen J,Quan M,Chen Z,et al.Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high:an open-label prospective pivotal trial[J].Cancer Res Clin Oncol,2020,146(10):2651-2657.
[10] Jiang FE,Zhang HJ,Yu CY,et al.Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer:an observational pilot study[J].Neoplasma,2021,68(4):861-866.
[11] Yi M,Jiao D,Qin S,et al.Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment[J].Mol Cancer,2019,18(1):60.
[12] Zhao S,Ren S,Jiang T,et al.Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer[J].Cancer Immunol Res,2019,7(4):630-643.
[13] Rao J,Xia J,Yang W,et al.Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer:a case report[J].Ann Transl Med,2020,8(23):1609.
[14] Cheng H,Zong L,Kong Y,et al.Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01):a single-arm,open-label,phase 2 trial[J].Lancet Oncol,2021,22(11):1609-1617.